Target intelligence / Profile preview

1,3-1,4-beta-D-glucan (MLG)

Target
MLG
Molecular classification
Polysaccharide, Dietary fiber, Carbohydrate, Pattern-associated molecular pattern (PAMP)
01

Overview

1,3-1,4-beta-D-glucan, commonly known as mixed-linkage glucan (MLG), is a linear polysaccharide composed of D-glucopyranosyl units linked by a combination of beta-(1->3) and beta-(1->4) glycosidic bonds (PubChem CID 439263). It is a major structural component of the cell walls in cereal grains such as oats and barley, and is also produced by certain bacteria and lichens (Journal of Cereal Science, 2010). While it is not a therapeutic target protein like a receptor or enzyme, it is a bioactive dietary fiber with significant clinical relevance in metabolic health (FDA 21 CFR 101.81). Its primary mechanism involves the formation of a high-viscosity gel in the small intestine, which traps bile acids and slows the absorption of glucose, thereby lowering LDL cholesterol and improving glycemic control (Nutrients, 2019). Additionally, it can act as an immunomodulator by interacting with pattern recognition receptors such as Dectin-1 (CLEC7A) on immune cells, although its activity is distinct from the more common fungal beta-1,3-glucans (Frontiers in Immunology, 2020). Clinically, it is utilized as a nutritional intervention for cardiovascular disease and type 2 diabetes rather than being a target for drug inhibition (EFSA Journal, 2011).

Other names
Mixed-linkage glucanCereal beta-glucanLicheninBarley beta-glucanOat beta-glucan(1->3),(1->4)-beta-D-glucan
02

Mechanism of action

Acts as a bioactive dietary fiber that forms a high-viscosity gel in the gastrointestinal tract to physically sequester bile acids and slow the absorption of glucose; also functions as a ligand for pattern recognition receptors like Dectin-1 to modulate innate immunity.

03

Biological functions

Structural component of plant cell wallsRegulation of lipid metabolismRegulation of glucose absorptionImmunomodulationBile acid sequestration
04

Disease associations

HypercholesterolemiaDiabetes mellitus type 2ObesityCardiovascular diseaseInflammation
05

Safety considerations

Gastrointestinal distress (e.g., bloating, flatulence, abdominal cramps)Potential reduction in the bioavailability of co-administered oral medications due to increased intestinal viscosityRare instances of hypersensitivity or allergic reactions
06

Biomarkers

Low-density lipoprotein (LDL) cholesterolPostprandial blood glucoseGlycated hemoglobin (HbA1c)C-reactive protein (CRP)

Beyond the preview

Go deeper on 1,3-1,4-beta-D-glucan (MLG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 1,3-1,4-beta-D-glucan (MLG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call